Inhibikase Loss Widens as Phase 3 PAH Trial Expands
WILMINGTON, DE— Inhibikase Therapeutics, Inc. (Nasdaq: IKT) nearly doubled its second-quarter net loss as spending increased on its Phase 3 pulmonary arterial hypertension program, while a subsequent $50 million stock …
Inhibikase Loss Widens as Phase 3 PAH Trial Expands Read More